Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Manhattan Scientifics, Inc. (MHTX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0116+0.0008 (+7.41%)
At close: 02:48PM EDT
Advertisement
Sign in to post a message.
  • J
    J
    Non-exciting 24% bump today on no news.
  • H
    High Desert
    "We have all ready had successful tests of diagnosis with respect to specific cancer's in human tissue. That's all ready happened"
    MHTX is at last count, the top holder of IBX stock and their former parent company, holding somewhere's between 50 million and 56 million shares. The above statement is from IBX's little known Pre-IPO investor call from 2017. Four very important gentleman were on that call and when one made the statement, none of the other's disputed it. Given the fact that iron oxide nano particles & targeting antibodies used for drug therapy have been in use in human's for over 20 years, coupled with IBX's stealthy NP coating that's all ready passed toxicity tests, not much remains to uncertainty of the tech's efficacy in the current and on going First In Humans trials. The statement comes at about the 22 minute mark, though I recommend listening to the entire call for context. Looking forward to a win/win outcome!
    https://imagionbiosystems.com/news/pre-ipo-investor-conference-call/
    On June 20, 2017, Imagion Biosystems President and CEO Bob Proulx provided an update and briefing on the pending Imagion Biosystems initial public
    On June 20, 2017, Imagion Biosystems President and CEO Bob Proulx provided an update and briefing on the pending Imagion Biosystems initial public
    imagionbiosystems.com
  • H
    High Desert
    A 30 year battle to commercialize bulk nanostructured metals and alloys has finally been achieved! Excellent news for all Manhattan Scientifics shareholders who have waited so long. Enjoy the victory!

    Almost 30 years of research elucidating the mechanisms and reproducibility of nanostructuring has enabled the progressive emergence of reliable methods to manufacture bulk nanostructured metallic materials with superior properties. This article reviews examples of the use of nanostructured metals in engineered products that are currently commercially available, or will soon become available for specific biomedical, aerospace, electronics, and energy industry applications. The examples illustrate how the making and marketing of nanostructured materials follow similar development stages as other new advanced materials, but with additional challenges at each stage. Challenges include the difficulties of scaleup, intricacies of nanoscale characterization, the lack of consensus standards for product quality, competition with long-established conventional materials, regulatory hurdles associated with nanoscale technology, and consumer/user education on the virtues and limitations of nanostructuring. Finally, we discuss how the experiences to date with nanostructuring by various methods have established precedents that can guide manufacturing process development for advanced nanostructured metal and alloy applications.
    Acknowledgments
    R.Z.V. gratefully acknowledges the financial support from the Russian Science Foundation in the framework of the Project No. 20-63-47027 for research in his part of the publication.

    Author information
    Affiliations
    Department of Metallurgical and Materials Engineering, Colorado School of Mines, Golden, USA

    Terry C. Lowe

    Institute of Physics of Advanced Materials, Ufa State Aviation Technical University, Ufa, Russia

    Ruslan Z. Valiev

    Department of Mechanical and Aerospace Engineering, and Department of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, USA

    Xiaochun Li

    Fort Wayne Metals, Fort Wayne, USA

    Benjamin R. Ewing

    Corresponding author
    Correspondence to Terry C. Lowe.

    Ethics declarations
    Conflict of interest
    On behalf of all authors, the corresponding author states that there is no conflict of interest.
  • m
    m
    Imagion Biosystems and Patrys to collaborate on brain tumor imaging.
    MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, and Patrys Limited (ASX: PAB), a therapeutic antibody development company, are pleased to announce a collaborative research program using their combined technologies to improve brain tumor imaging and diagnosis.

    Patrys’ novel deoxymabs are attracted to the DNA fragments released from dying tumor cells and are able to penetrate and kill tumor cells. The collaboration aims to pair the targeting specificity of the deoxymabs with the imaging capabilities of the MagSense® technology to provide a highly effective imaging agent with high specificity for hard-to-diagnose cancers such as brain cancer.

    “We are very interested in the tumor targeting capabilities of the Patrys deoxymabs and believe there is potential for Patrys’ deoxymabs to be paired with our MagSense® nanoparticles for many types of solid tumors,” said Bob Proulx, Executive Chairman of Imagion Biosystems.

    “Initially, we are very keen to investigate the potential for brain tumor imaging since there is such a high unmet need for differentiating cancerous tumors in the brain, like glioblastoma, as well as metastatic disease that has spread to the brain from other primary tumors.

    “The combination of our two company’s technologies offers a range of exciting opportunities”, said Dr. James Campbell, Patrys’ CEO and Managing Director. “The potential for our deoxymab antibodies to home in on a range of different cancer types due to their affinity for DNA is one of the properties that makes them so unique and opens up a range of different clinical applications for their use.

    “We are very excited to be further leveraging the cancer-targeting ability deoxymabs by partnering with Imagion and its innovative MagSense® imaging technology to potentially develop new ways to visualize and diagnose cancer.”

    Preliminary research efforts by Imagion have demonstrated that the Patrys PAT-DX1 molecule can be conjugated to the MagSense® nanoparticles and provide bio-functionality for targeting certain cancer cell lines. Should this further collaborative work provide positive results, Imagion will have an exclusive option to a future license agreement, should it elect to commercialize the imaging agent. Under the current collaboration both parties are bearing their own costs.

    Brain tumors are neoplasms arising from cells of the central nervous system (CNS) including primary tumors originating in the brain and secondary tumors arising from metastases to the brain. Secondary brain tumors are significantly more frequent, affecting one in four cancer patients. Of the more than 300,000 individuals afflicted with malignant brain cancer each year globally, less than 25% survive beyond five years. Conventional MRI has been the standard modality to identify and localize tumors in the brain for many years, but a biopsy is the only definitive way they can be diagnosed and two-thirds of primary brain tumors are benign. A non-invasive imaging method able to specifically identify malignant brain tumors and differentiate from benign disease would address a significant unmet medical need.
  • m
    m
    Imagion to work with Boston University on next generation imaging technology 
     
    MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has become a member of the Nanosystems Engineering Research Center at Boston University, where researchers are developing ultrasensitive magnetic sensors that could greatly simplify the MagSense™ detection system. If successful, the new sensors could enable the use of MagSense cancer detection technology in a doctor’s suite in addition to a hospital imaging suite.

    The Center, funded by the US National Science Foundation (NSF), is developing next generation cellular metamaterials technologies with a primary focus on advancing nano-bio-manufacturing methods. Membership provides Imagion with priority access to the new technologies and intellectual property being developed at the Center. Of specific interest to Imagion is the Center’s advancements in the use of Micro-Electro-Mechanical systems (MEMs) as ultrasensitive magnetometers which may have application in detecting cardiovascular events and bio-medical imaging. MEMs are ubiquitous in everyday technologies such as cellular phones and gaming devices providing functionality such as accelerometers, gyroscopes and even in microphones.  For Imagion, MEMs-based sensors could significantly reduce the size and cost of the MagSense system by eliminating the requirement of using cryogenically cooled sensors, making it both more affordable and portable like ultrasound equipment used in a doctor’s office.

    “We are very excited by the research being done at Boston University on super small highly sensitive magnetic sensors,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “Historically, we have focused on using known technologies like superconducting quantum interference devices, so-called SQUIDs, because they are proven technologies.  Having visibility and access to cutting-edge innovative technologies through our membership with the Center could enable us to produce imaging systems that don’t need cryogenic cooling and are more versatile, expanding the commercial opportunity for our MagSense system.”

    “We are pleased to welcome Imagion Biosystems to the Center,” said Dr. David Bishop, Head of the Division of Materials Science and Engineering at Boston University and Director of the Center. “We are always keen to have industry partners as members to help focus our research projects on practical applications that can translate from academic research to commercial value. We see Imagion’s MagSense technology as being a good match and look forward to collaborating with them.”
     -ENDS

    About the Nanosystems Engineering Research Center
    Officially known as the Nanosystems Engineering Research Center for Directed Multiscale Assembly of Cellular Metamaterials with Nanoscale Precision (CELL-MET), the Center, led by Boston University, was established to leverage the financial support provided by the National Science Foundation in creating opportunities for public and private collaboration in research and development of new nanoscale technologies. Industry and academic members of the Center provide input to research projects prioritized by the Center and have priority access to inventions for research and commercial purposes.

    About Imagion Biosystems
    Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
  • H
    High Desert
    An informative piece about Manhattan's latest spun out Imagion Biosystems which provides a nice overview about the company & it's technology. MHTX is currently the largest shareholder with over 50 million shares.
    https://www.dailymotion.com/video/x7xf5zl
  • D
    David
    Quote from today's MHTX..."We expect to start earing royalties in 2021. The Company’s NANOMETALS hold the potential to dramatically alter the medical prosthetics industry."
  • D
    David Blatner
    Fort Wayne Metals titanium ECAP-C work just written about here in the latest 2nd Quarter "Titanium Today" Medical Edition on page 14 of magazine put out 3 weeks ago under "Titanium, Zirconia Vie for Dental Implant Applications: Improvements from C-ECAP Technology Under Review"...

    https://issuu.com/titaniumtoday/docs/titaniumtoday_medical20_072120
    TITANIUM TODAY Medical 2 Qtr 2020 Issue 29; 2020
    TITANIUM TODAY Medical 2 Qtr 2020 Issue 29; 2020
    issuu.com
  • J
    Joseph
    My good friend sells a pharmaceutical for HER2 breast cancer. I have sold both CT, MRI and Nuclear Medicine products. If this works, it really could be a game changer - more specific, no radiation, and the possibility of not having to remove the lymph nodes. I'm NOT pumping this stock - I am long. Besides success with clinical trials, there is RISK of financing falling through, so don't invest your life savings. However, given the potential for not only breast cancer, this could expand into other cancer diagnostics, so there is incredible upside potential.
    Bullish
  • m
    m

    Imagion Biosystems Phase I study update: Submission for ethics approval filed

    MELBOURNE — Imagion Biosystems (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense™ product for the detection of HER2 metastatic breast cancer.

    The company has completed preparations of the requisite materials for a Human Research Ethic Committee (HREC) review and has submitted its Phase I study for HREC review and approval.  The HREC review and approval process provides an independent review of scientific and ethical considerations of proposed human research in Australia.  Given the normal review cycle for Phase I studies, the Company expects the review process to be consistent with its plans to start the study in Q4, noting that approval is not guaranteed and may require additional information or dialog with the Committee.

    Additionally, the Company has confirmed three study sites, two in Melbourne and one in Sydney, plan to participate in the study.  Additional sites are being consider and will be added to the study, if possible, to maximize the opportunity for enrolment of qualified subjects in a timely manner.

    “We believe our regulatory and clinical team has put together a strong and compelling study and look forward to engaging with the HREC to gain approval,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “We are mindful of the ongoing risk arising from the COVID-19 pandemic. The potential disruption to hospital systems and their ability to treat cancer patients and undertake clinical studies continues to be high on our watch list. However, we do note that, presently under the current restrictions, Australian patients are allowed to travel for medical reasons and that cancer treatment is considered not only an essential service but crucial to delivering better health outcomes. In the meantime, we will continue to make ready and keep investors informed as near the planned start of the study and as we learn more from our clinical sites.”
     -ENDS-

    Authorisation & Additional information
    This announcement was authorised by the Robert Proulx, Executive Chair of Imagion Biosystems Limited

    About Imagion Biosystems
    Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

    For further information please visit www.imagionbiosystems.com

    Australian Media & Investor Relations
    Kyahn Williamson, WE Communications
    we-AUimagionbiosystems@we-worldwide.com
    +61-3-9866-4722

    U.S. Media Contact:
    Matthew Wygant
    matthew@biotechwriting.com
    +1-408-905-7630

    Imagion Biosystems Limited
    ACN 616 305 027
    Level 25, 525 Collins Street, Melbourne VIC 3000 www.imagionbiosystem.com

    



    Cancer detection with better specificity and sensitivity without exposure to radiation
    Cancer detection with better specificity and sensitivity without exposure to radiation
    www.imagionbiosystems.com
  • J
    J
    As someone who formally sold MRI contrast, this nanoparticle imaging system by Imagion could really be a game-changer. I am VERY encouraged that the 76,538,864 shares issued did not dilute the price of either Imagion or Manhattan Scientific. Or, have they not yet been sold? The date of the announcement was yesterday.
    Bullish
  • m
    m
    Imagion Biosystems enters agreement to develop nanocrystals for treating breast cancer
     
    MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has entered into a Joint Development Agreement with Global Cancer Technology (GCT), to develop GCT’s novel nanoscintillator technology for the treatment of breast cancer (see Nanoscintillator description below). Under the terms of the Agreement, Imagion will be paid for certain R&D services while gaining an ownership interest in the arising GCT nanoscintillator product.

    “We are very interested in the unique potential of the nanoscintillator technology and the prospect of leveraging our nanoparticle expertise to develop cancer therapies,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “We have been working with GCT for this past year and have progressed to the point where we now see a path to product development. This project is value adding to our mission of developing nanoparticle-based imaging agents and therapies. As we continue to develop the MagSense® imaging technology, the nanoscintillators provides Imagion with a foothold to a unique high value therapeutic product.”

    “Imagion has demonstrated they have expertise in developing nanoparticle technologies”, said John Clark, CEO of Global Cancer Technology. “It was important for us to find a partner that understood the complexities of working with nanoparticles for human use and we are excited to get started with the development of this promising new technology.”

    About Nanoscintillators
    The nanoscintillator technology, also known as scintillating nanocrystals, has been licensed by GCT from the University of California San Diego. Scintillators are nontoxic minerals and rare earth elements that emit photons (light) when activated by a low dose of gamma radiation. Photocleavable linkers release a drug payload when exposed to the small burst of light from the scintillating photons. Since the drug molecules are inactive while linked to the nanoparticle, the nanoscintillator technology enables a controlled release of the therapeutic agent. This next generation approach, known as x-ray induced photodynamic therapy, has the potential to deliver a more localized and effective dose of drug product to treat cancers because x-rays can penetrate deep tissue. There are more than 400 dedicated stereotactic radiosurgery systems in the US that could be used in combination with the nanoscintillator therapy.

    -ENDS
     

    Authorisation & Additional information

    This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited
  • H
    High Desert
    Of interest in regards to Metallicum's efforts to provide Nano Structured Aluminum overhead high voltage DC lines to the grid.
    GE has developed an efficient way to convert High Voltage DC (the most efficient way to transmit Solar/Wind energy long distance's) back to High Voltage AC (for use to consumer's). Couple this with Metallicum's Nano Structured Aluminum that can save most of that 7% loss of energy in the transmission of power from the source to the user, and the concept gains appeal.
    https://www.pppl.gov/news/2018/08/protecting-power-grid-advanced-plasma-switch-can-make-grid-more-efficient-long-distance
    Inside your home and office, low-voltage alternating current (AC) powers the lights, computers and electronic devices for everyday use. But when the electricity comes from remote long-distance sources such as hydro-power or solar generating plants, t
    Inside your home and office, low-voltage alternating current (AC) powers the lights, computers and electronic devices for everyday use. But when the electricity comes from remote long-distance sources such as hydro-power or solar generating plants, t
    www.pppl.gov
  • J
    J
    This could be a great accumulation period for MHTX. Keep an eye on the IBXX share price.
  • H
    High Desert
    NEW'S Nano Metal: https://www.businesswire.com/news/home/20181212005182/en/
    -Manhattan Scientifics Inc. (OTCQB: MHTX), today announced that the company is involved in discussions to license its nano-metals technology and related intellectual property to a medical industry metals manufacturer.

    Manhattan Scientifics has to date received $500,000 good faith and machinery payments from the sale of equipment to the manufacturer.

    Discussions with this manufacturer have been on-going for an extended period. The closing of such agreement is subject to continued due diligence, drafting a definitive agreement and approval of our Board of Directors. There can be no guarantee that we will satisfactorily conclude a commercial arrangement with this manufacturer.
  • H
    High Desert
    https://imagionbiosystems.com/news/imagion-announces-plan-to-undertake-first-clinical-study-in-australia/
    An expanded two pronged study with its new collaboration partner "Siemens Healthineers" WOW!
    Imagion announces plan to undertake first clinical study in Australia Live Webcast Scheduled Imagion Biosystems Limited (ASX: IBX), a company dedicated to
    Imagion announces plan to undertake first clinical study in Australia Live Webcast Scheduled Imagion Biosystems Limited (ASX: IBX), a company dedicated to
    imagionbiosystems.com
    Bullish
  • z
    zzzz
    It's been years since I have been on any chat board. And there's a reason for this. I see the same old pumper's that have absolutely no credibility at all. I see them on other stocks on boards I own as well. Do your own research. Now on to what I think about this company. This is one of my favorite lottery tickets if you will. My biggest fear when this goes to the next level is that it'll sell to a big Pharma and we will not get the true dollar amount that I think this can go to. This could pop to the level of a "Genentech" level. Sell it to a big Pharma and we share holders will never see the money. It's best to not tell to many others about MHTX as this is the main one I'm counting on to bring me a fortune I've dreamed of. I'm still accumulating!!!
  • W
    WALTER
    @high desert. Are you buying on the drops?....you bet I am! Back channel news is encouraging.
  • D
    David Blatner
    A Japanese patent was granted to MHTX a few months ago. The original patent was issued to Carpenter Technology Corp, but was released to MHTX, as part of settlement, in 2015 and is now being licensed to Fort Wayne Metals. There are almost a dozen other foreign countries that this grant is still being reviewed...

    https://patents.google.com/patent/JP6845690B2/en
    Bullish
  • m
    m
    IMAGION ANNOUNCES HREC APPROVAL FOR
    PHASE I STUDY

    MELBOURNE — Imagion Biosystems (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense™ HER2 Phase I study for metastatic breast cancer. With the study now approved the Company can proceed with finalising contracts with individual study sites.

    Additionally, the Company reports that manufacturing of the MagSense™ HER2 nanoparticle formulation for the study remains on track, having successfully completed bulk batch production. The company expects to complete the final step of Good Manufacturing Practice (GMP) compliant packaging of the material on time to support the start of the study. 

    Imagion Biosystems Executive Chairman Bob Proulx said, “We are very pleased with our progress and will now be working diligently with our planned study sites to commence the study this calendar quarter as we have previously advised.”
Advertisement
Advertisement